A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors

Cancer Clinical Trial

Official title:

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05351502
• Other study ID #: BA-ONC-01
• Status: Recruiting
• Phase: Phase 1
• Start date: August 14, 2022
• Est. completion date: April 1, 2025

Study information

• Verified date: April 2023
• Source: Beyond Air Inc.
• Contact: Edith Dekel
• Phone: 972-50-8464449
• Email: edekel[@]beyondcancer.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label, dose-escalation and dose-expansion study comprised of a screening period, a single treatment session, an evaluation period of 21±3 days, and safety and survival follow-up period of up to 12 weeks post-treatment.

Description:

The purpose of this Phase 1 study is to initiate clinical development of gNO in patients with unresectable cutaneous or subcutaneous primary or metastatic solid tumors that are not amenable or have failed standard treatment, for which no therapy of proven efficacy exists, or which has progressed despite standard therapy. This study of gNO treatment will consist of 2 parts: a dose-escalation part to establish a safe and tolerable dose of gNO in patients with primary or metastatic unresectable cutaneous or subcutaneous solid tumors (Part A), and a dose expansion phase (Part B) which may be initiated at the Sponsor's discretion after the maximum tolerated dose (MTD) and/or optimal biological dose (OBD) (or recommended Phase 2 dose [RP2D]) has been determined in the dose-escalation phase (Part A). This study will be the basis for future studies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: April 1, 2025
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient (male or female) is at least 18 years of age at the time of signature of the informed consent form.

• Patient has an ECOG Performance Status score of 0-3 and with a life expectancy of =3 months.

• Patient must have a confirmed diagnosis of at least one unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor. Up to five target lesions may be identified.

• No therapy of proven efficacy exists for the tumor, the tumor is not amenable to standard therapies, the tumor has failed to respond to standard therapy or has progressed despite standard therapy.

• Patient has measurable disease on imaging based on RECIST Version 1.1.

• Patient have adequate hematologic and organ function.

• Patient have not had radiotherapy to the targeted lesions within the preceding 12 months.

• Superficial tumor axis minimum length and depth of 4.5mm. .

• Patient is not with childbearing potential or agrees to use adequate contraceptive methods

Exclusion Criteria:

• The tumor is situated in the lymph node, in thyroid, close to trachea or in facial area or other region which, in the Investigator's opinion, can pose extra risk to the patient.

• Has received prior systemic anti-cancer therapy including investigational agents within 14 days of the start of study treatment.

• Active central nervous system tumors or metastases..

• Received systemic corticosteroid therapy =1 week prior to study treatment or any other form of systemic immunosuppressive medication for medically significant acute or chronic conditions.

• Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, neuropathy and protocol-defined laboratory values.

• Active or prior documented autoimmune or inflammatory disorders.

• History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of enrolment.

• Known active infection and uncontrolled intercurrent illness.

• Receiving drugs that have contraindication with NO.

• Patient is receiving anticoagulants including low molecular weight heparin.

Related Conditions & MeSH terms

• Cancer
• Neoplasm Metastasis

Intervention

Drug:
• Nitric Oxide 25,000 ppm
Intratumoral injection of 25,000 gNO
• Nitric Oxide 50,000 ppm
Intratumoral injection of 50000 gNO
• Nitric Oxide 100,000 ppm
Intratumoral injection of 100,000 gNO
• Nitric Oxide selected dose
Intratumoral injection of selected does on gNO

Locations

Country	Name	City	State
Israel	Soroka Medical Center	Be'er Sheva
Israel	Hadassah Ein-Karem	Jerusalem
Israel	Sheba Medical Center	Ramat Ef'al
Israel	Sourasky Tel Aviv Medical Center	Tel Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Beyond Air Inc.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assessment of predictive biomarkers for anti-tumor activity of a single intratumoral gNO injection	Measurement of blood immune biomarkers levels	up to Day 21 from injection
Primary	Incidence of AEs, SAEs and DLTs (safety) parameters.	The incidence and characteristics of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs) and changes in assessed safety parameters. Toxicity will be graded according to NCI CTCAE version 5.0	up to12 weeks from injection
Secondary	Anti-tumor activity of a single intratumoral gNO injection at all administered doses	The anti-tumor activity of a single intratumoral gNO injection will be measured per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and secondarily immune-related RECIST (iRECIST).	up to Day 21 from injection

External Links

•   Confino H., et al. Intratumoral administration of high-concentration nitric oxide and anti PD-1 treatment leads to higher tumor regression rates and prolonged survival in CT26 tumor-bearing mice SITC 2022
•   Meirovitz A., et al. Phase 1 study of ultra-high concentration nitric oxide (UNO) in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies. SITC 2023